Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 2180567 | 4 pages | https://doi.org/10.1155/2019/2180567

A Case of a Persistent Postoperative Infection Caused by Multidrug-Resistant Kluyvera ascorbata in the Oral and Maxillofacial Region

Academic Editor: Paola Di Carlo
Received02 Oct 2018
Revised29 Dec 2018
Accepted09 Jan 2019
Published31 Jan 2019

Abstract

Introduction. Kluyvera ascorbata infection is rare, but it has been extensively studied because of its potential to cause a wide range of infections and its ability to transfer the gene encoding for CTX-M-type extended spectrum β-lactamases (ESBLs) to other Enterobacteriaceae. Case Presentation. The authors report a case of a 61-year-old Chinese male with a persistent postoperative infection caused by a multidrug-resistant ESBL-producing K. ascorbata. Following antimicrobial susceptibility testing, he was aggressively treated with gentamicin and levofloxacin with a favorable outcome. Conclusion. To our knowledge, this is the first case report of a persistent postoperative infection caused by a multidrug-resistant K. ascorbata in the oral and maxillofacial region. The authors suggest that K. ascorbata infection warrants prompt identification and aggressive antibiotic management, given that ESBL-producing K. ascorbata is resistant to penicillins and first-generation to third-generation cephalosporins.

1. Introduction

Kluyvera ascorbata is a Gram-negative microorganism belonging to the family of Enterobacteriaceae and was first identified by Farmer et al. [1]. Although it infrequently causes infections, it can cause a wide range of infections including acute appendicitis [2]; biliary tract infection [3]; urinary tract infection [4]; bacteremia with neutropenia and fever [5]; bacteremia and severe sepsis [6]; sepsis accompanied with multiorgan dysfunction [7]; hock and pulmonary hemorrhage [8]; enteritis, central venous catheter infections, and peritonitis [9, 10]; solid organ transplant recipient infection [11]; acute cholecystitis [12]; and cholecystitis and bacteremia [13]. However, no K. ascorbata infections have been reported to date in the oral and maxillofacial region. Therefore, the authors describe the first case of a persistent postoperative infection caused by K. ascorbata in the oral and maxillofacial region after a combination of radical neck dissection with gingivectomy and mandibulectomy. A brief literature review of the clinical features of K. ascorbata infections in humans is also included.

2. Case Presentation

A 61-year-old Chinese man was admitted to hospital with a gingival squamous cell carcinoma of the left mandible. He was treated with a combination of radical neck dissection with gingivectomy, mandibulectomy, and strengthening of the mandible with a reconstructive plate (Figure 1). K. ascorbata was identified from the drainage specimen taken on postoperative day five and confirmed with the Hefei Star HX-21 blood culture analyzer (Hefei Star Technology Development Co., Ltd., Anhui, China). Antimicrobial susceptibility testing showed resistance to cefazolin and piperacillin but susceptibility to levofloxacin and gentamicin (Table 1). K. ascorbata’s ability to produce ESBLs was also detected by the same system. The patient’s blood culture was sterile. Intravenous administration of levofloxacin (200 mg, q24 h) and gentamicin (240 mg, q24 h) based on the susceptibility test of this microorganism was continued for 14 days. The wounds were continuously dressed twice a day for 2 weeks and daily for 1 week. The patient was discharged home with an iodoform sponge which was changed weekly for 1 month, and the wound gradually healed after 2 months.


NameGroupMIC (μg/ml)AST

CefazolinA≥8Resistant
AmpicillinA≥32Resistant
GentamicinA≤2Sensitive
PIZB≥128/4Resistant
PiperacillinB≥128Resistant
CefuroximeB≤4Resistant
CefotaximeB≥64Resistant
CefepimeB≤4Sensitive
ImipenemB≤1Sensitive
AmikacinB≤8Sensitive
CiprofloxacinB≤0.25Sensitive
LevofloxacinB≤1Sensitive
SXTB≤0.5/9.5Sensitive
AztreonamC≥16Resistant
CeftazidimeC≤4Resistant
ChloramphenicolC≤4Sensitive
CefoperazoneO≤8Sensitive
MinocyclineO≤2Sensitive
CPSO≥64/64Resistant
NitrofurantoinU≥128Resistant
OfloxacinU≤1Sensitive

Dose and usage are for adults. Group A (drug of first choice): priority selection; Group B (drug of first choice): selection of drug resistance or nonuse in Group A; Group C: selection of drug resistance or nonuse in Group A and B; A supplement to the urethra; Group O: other drugs. Kluyvera ascorbata with the ability to produce extended spectrum beta-lactamases is resistant to penicillins, first-generation to third-generation cephalosporins, and most beta-lactams, even with a sensitive result in vitro.

3. Discussion

K. ascorbata is a relatively newly described member of the Enterobacteriaceae family that rarely causes infections in humans. These bacteria are usually considered a commensal [8]. Nosocomial infections pose significant threats to hospitalized patients, especially immunocompromised patients, such as those with cancer [14]. The authors report what they believe to be the first case of a multidrug-resistant K. ascorbata isolated from the wound drainage specimen of an inpatient with a postoperative infection.

K. ascorbata is virulent in terms of clinical features. It causes a wide range of infections over a wide age span, namely, from adults as old as 78 years [15] to children [9], infants [16], low birth weight infants [8], and neonates as young as five days old [17]. The authors report a case involving a 61-year-old patient.

Kluyvera species can be isolated from sputum, urine, stools, and blood [18, 19], hospital sewage [20], human milk samples [21], as well as wound drainage specimens as in our case.

Kluyvera strains are rare but potentially dangerous pathogens due to their ability to transfer the gene encoding for ESBLs [18], which was elucidated by Literacka et al. [22]. CTX-M beta-lactamases, which are plasmids mediated in other Enterobacteriaceae, originate from the chromosomal beta-lactamases of its reservoir, K. ascorbata. ISEcp1B, which is an insertion element [23] and a genetic mobile element [24], has been reported to be associated with gene transfer [25, 26]. Besides blaCTX-M-3, K. ascorbata also bears the blaTEM-1, aacC2, and armA genes, as well as integronic aadA2, dfrA12, and sul1, which together confer resistance to the majority of beta-lactams, aminoglycosides, and trimethoprim-sulfamethoxazoles [27]. Antimicrobial agents active against Kluyvera strains include third-generation cephalosporins, fluoroquinolones, aminoglycosides [8], beta-lactams with beta-lactamase inhibitors and carbapenems [7], and meropenem [26]; however, as shown by the authors, ESBL-producing K. ascorbata is resistant to penicillins and first-generation to third-generation cephalosporins. Clinicians should be aware of the spectrum of disease and the increasing clinical importance of this pathogen. Purified KLUA-9 from K. ascorbata showed the highest catalytic efficacy towards benzylpenicillin, ampicillin, piperacillin, first-generation cephalosporins, cefuroxime, and cefoperazone and the lowest efficacy towards dicloxacillin, cefoxitin, and imipenem [28].

K. ascorbata, which is a potentially dangerous pathogen in both immunocompetent and immunocompromised hosts, warrants prompt identification by antimicrobial susceptibility testing and a correct and aggressive antibiotic management [16, 29].

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

Acquisition, analysis, and interpretation of data were performed by Si-Hai Zou, Lu-Ying Zhu, and Yong Li. Drafting or revision and final approval of the article were performed by Fu-Gui Zhang.

Acknowledgments

We are grateful to Qi-Ming Wang and Cheng Deng for providing technical support. We extend our sincere thanks to Yan Sun for proofreading the microbiological part. We thank Helen Jeays, BDSc AE, from Liwen Bianji, Edanz Editing China (http://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript. This study was sponsored by the National Natural Science Foundation of China (No. 81400493), High-level Medical Reserved Personnel Training Project of Chongqing, Scientific Research Project of Chongqing Health Commission (No. 2017MSXM074), and project supported by the Program for Innovation Team Building at Institutions of Higher Education in Chongqing in 2016.

References

  1. J. J. Farmer III, G. R. Fanning, G. P. Huntley-Carter et al., “Kluyvera, a new (redefined) genus in the family enterobacteriaceae: identification of Kluyvera ascorbata sp. nov. and Kluyvera cryocrescens sp. nov. in clinical specimens,” Journal of Clinical Microbiology, vol. 13, pp. 919–933, 1981. View at: Google Scholar
  2. J. E. Carter and T. N. Evans, “Clinically significant Kluyvera infections: a report of seven cases,” American Journal of Clinical Pathology, vol. 123, no. 3, pp. 334–338, 2005. View at: Publisher Site | Google Scholar
  3. L. Wang, Y. Jing, K. Lai, J. An, and J. Yang, “A case of biliary tract infection caused by KPC-2-producing Kluyvera ascorbata,” Case Reports in Infectious Diseases, vol. 2018, Article ID 5745708, 2 pages, 2018. View at: Publisher Site | Google Scholar
  4. H. Narchi, “Kluyvera urinary tract infection,” Pediatric Infectious Disease Journal, vol. 24, no. 6, pp. 570–572, 2005. View at: Publisher Site | Google Scholar
  5. P. Linares, C. Castanon, C. Llano et al., “Bacteremia by Kluyvera ascorbata in a patient with neutropenia and fever,” Enfermedades Infecciosas y Microbiología Clínica, vol. 18, no. 1, pp. 48-49, 2000. View at: Google Scholar
  6. M. Alfreijat, “A case of urinary tract infection and severe sepsis caused by Kluyvera ascorbata in a 73-year-old female with a brief literature review,” Case Reports in Infectious Diseases, vol. 2017, Article ID 3848963, 2 pages, 2017. View at: Publisher Site | Google Scholar
  7. E. Karadag Oncel, Y. Ozsurekci, Y. Akyon, D. Gur, A. B. Cengiz, and A. Kara, “Kluyvera ascorbata infections in children: a case series,” Türk Pediatri Arşivi, vol. 50, no. 2, pp. 123–128, 2015. View at: Publisher Site | Google Scholar
  8. D. Sharma, T. Dasi, S. Murki, and T. P. Oleti, “Kluyvera ascorbata sepsis in an extremely low birth weight infant,” Indian Journal of Medical Microbiology, vol. 33, no. 3, p. 437, 2015. View at: Publisher Site | Google Scholar
  9. E. Ruffini, F. Pace, M. Carlucci, E. De Conciliis, P. Staffolani, and A. Carlucci, “Urinary tract infection caused by Kluyvera ascorbata in a child: case report and review of the Kluyvera infections in children,” Minerva Pediatrica, vol. 60, no. 6, pp. 1451–1454, 2008. View at: Google Scholar
  10. R. Yogev and S. Kozlowski, “Peritonitis due to Kluyvera ascorbata: case report and review,” Clinical Infectious Diseases, vol. 12, no. 3, pp. 399–402, 1990. View at: Publisher Site | Google Scholar
  11. R. Cheruvattath, V. Balan, R. Stewart, R. L. Heilman, D. C. Mulligan, and S. Kusne, “Kluyvera co-infection in two solid organ transplant recipients: an emerging pathogen or a colonizer bystander?” Transplant Infectious Disease, vol. 9, no. 1, pp. 83–86, 2007. View at: Publisher Site | Google Scholar
  12. N. Batista, Ó. Díez, A. Moreno, and J. Ode, “Colecistitis aguda por Kluyvera ascorbata,” Enfermedades Infecciosas y Microbiología Clínica, vol. 20, no. 7, pp. 370-371, 2002. View at: Publisher Site | Google Scholar
  13. J. Oteo, J. Luis Gómez-Garcés, and J. I. Alós, “Acute cholecystitis and bacteremia caused by Kluyvera ascorbata in a cirrhotic patient,” Clinical Microbiology and Infection, vol. 4, no. 2, pp. 113–115, 1998. View at: Publisher Site | Google Scholar
  14. H. M. Ashour and A. El-Sharif, “Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients,” Journal of Translational Medicine, vol. 7, no. 1, 2009. View at: Publisher Site | Google Scholar
  15. G. Lopez-Larramona, E. Gomez-de-Ona, M. M. Maestre-Muniz, A. M. Ruiz-Chicote, E. Galan-Dorado, and L. Gonzalez-Delgado, “Kluyvera ascorbata bacteremia in an adult patient,” Revista Española de Quimioterapia, vol. 26, p. 226, 2013. View at: Google Scholar
  16. A. Isozaki, K. Shirai, S. Mimura, M. Takahashi, W. Furushima, and Y. Kawano, “A case of urinary tract infection caused by Kluyvera ascorbata in an infant: case report and review of the literature,” Journal of Infection and Chemotherapy, vol. 16, no. 6, pp. 436–438, 2010. View at: Publisher Site | Google Scholar
  17. F. Ochi, H. Tauchi, M. Mizumoto, H. Miyamoto, and E. Ishii, “Kluyvera ascorbata infection in a neonate,” Pediatrics International, vol. 59, no. 5, pp. 640-641, 2017. View at: Publisher Site | Google Scholar
  18. R. Carrillo Esper, C. Pena Perez, J. Mucino Bermejo, J. R. Carrillo Cordova, and L. D. Carrillo Cordova, “Severe sepsis, septic shock and secondary multiple organ dysfunction in infection by Kluyvera ascorbata,” Gaceta Médica de México, vol. 147, no. 4, pp. 355–360, 2011. View at: Google Scholar
  19. E. Padilla, P. Tudela, M. Gimenez, and J. M. Gimeno, “Kluyvera ascorbata bacteremia,” Medicina Clínica, vol. 108, no. 12, p. 479, 1997. View at: Google Scholar
  20. F. Zhao and Z. Zong, “Kluyvera ascorbata strain from hospital sewage carrying the mcr-1 colistin resistance gene,” Antimicrobial Agents and Chemotherapy, vol. 60, pp. 7498–7501, 2016. View at: Publisher Site | Google Scholar
  21. P.-W. Chen, S.-Y. Tseng, and M.-S. Huang, “Antibiotic susceptibility of commensal bacteria from human milk,” Current Microbiology, vol. 72, no. 2, pp. 113–119, 2015. View at: Publisher Site | Google Scholar
  22. E. Literacka, B. Bedenic, A. Baraniak et al., “blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1630–1635, 2009. View at: Publisher Site | Google Scholar
  23. P. Nordmann, M.-F. Lartigue, and L. Poirel, “Beta-lactam induction of ISEcp1B-mediated mobilization of the naturally occurring (CTX-M) beta-lactamase gene of Kluyvera ascorbata,” FEMS Microbiology Letters, vol. 288, no. 2, pp. 247–249, 2008. View at: Publisher Site | Google Scholar
  24. C. Humeniuk, G. Arlet, V. Gautier, P. Grimont, R. Labia, and A. Philippon, “β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 9, pp. 3045–3049, 2002. View at: Publisher Site | Google Scholar
  25. M.-F. Lartigue, L. Poirel, D. Aubert, and P. Nordmann, “In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring β-lactamase gene blaCTX-M of Kluyvera ascorbata,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1282–1286, 2006. View at: Publisher Site | Google Scholar
  26. S. Moonah, K. Deonarine, and C. Freeman, “Multidrug resistant Kluyvera ascorbata septicemia in an adult patient: a case report,” Journal of Medical Case Reports, vol. 4, no. 1, p. 197, 2010. View at: Publisher Site | Google Scholar
  27. M. Golebiewski, I. Kern-Zdanowicz, M. Zienkiewicz et al., “Complete nucleotide sequence of the pCTX-M3 plasmid and its involvement in spread of the extended-spectrum β-lactamase gene blaCTX-M-3,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 11, pp. 3789–3795, 2007. View at: Publisher Site | Google Scholar
  28. M. M. Rodríguez, P. Power, C. Bauvois et al., “Characterisation of KLUA-9, a β-lactamase from extended-spectrum cephalosporin-susceptible Kluyvera ascorbata, and genetic organisation of blaKLUA-9,” International Journal of Antimicrobial Agents, vol. 29, no. 3, pp. 332–337, 2007. View at: Publisher Site | Google Scholar
  29. D. Torre, E. Crespi, M. Bernasconi, and P. Rapazzini, “Urinary tract infection caused by Kluyvera ascorbata in an immunocompromised patient: case report and review,” Scandinavian Journal of Infectious Diseases, vol. 37, no. 5, pp. 375–378, 2009. View at: Publisher Site | Google Scholar

Copyright © 2019 Si-Hai Zou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1074 Views | 249 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.